Prescient Therapeutics: what has changed since the last PTX100 CTCL update

Small Caps speaks with Prescient Therapeutics (ASX: PTX) for a general company update focused on what has changed since our last interview on PTX100 in cutaneous T-cell lymphoma (CTCL). Management discusses the most important recent developments, what has or has not been validated since earlier clinical commentary, key risks around the phase 2A program, and the public milestones investors can watch next. This interview is based on the prior Small Caps PTX100 interview context and the company’s Q4 FY26 quarterly update.